Application of dual targeting drug delivery system for the improvement of anti-glioma efficacy of doxorubicin
| Autor: | Man Wang, Huanlong Qin, Linsheng Huang, Renyuan Gao, Cheng Kong, Xuebing Yan, Xiao Qu, Zhenliang Sun, YiBo Liu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Angiogenesis medicine.medical_treatment Brain tumor tumor affinity peptide 03 medical and health sciences 0302 clinical medicine Glioma medicine Doxorubicin Receptor Chemotherapy interleukin-4 receptor business.industry nanoparticle anti-glioma solid tumors medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Drug delivery Immunology Cancer research Nanocarriers business medicine.drug Research Paper |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| Popis: | // Zhenliang Sun 1, 2, * , Xuebing Yan 1, * , YiBo Liu 3 , Linsheng Huang 1 , Cheng Kong 1 , Xiao Qu 1 , Man Wang 2 , Renyuan Gao 1 and Huanlong Qin 1 1 Department of General Surgery, Shanghai Tenth People’s Hospital Affiliated to Tongji University, Shanghai 200072, China 2 Shanghai Jiaotong University Affiliated Sixth People’s Hospital, South Campus, Shanghai 201499, China 3 Longhua Hospital of Shanghai University of TCM, Shanghai 200032, China * These authors contributed equally to this work Correspondence to: Huanlong Qin, email: huanlong_qin@live.cn Man Wang, email: man_wang1@163.com Keywords: tumor affinity peptide, interleukin-4 receptor, solid tumors, anti-glioma, nanoparticle Received: February 06, 2017 Accepted: June 17, 2017 Published: July 13, 2017 ABSTRACT Chemotherapy of glioma is always hampered by the unsatisfactory tumor accumulation of drugs, of which the most noticeable obstacle is the limited drug permeability from vessels into tumor inner. In the present study, we developed a novel nanocarrier for the delivery of doxorubicin to brain tumor. Such novel drug delivery system was mainly composed of a tumor homing peptide and DOX-loaded PLA nanoparticles (AP1-NP-DOX). CRKRLDRNC peptide, named as AP1, was a newly glioma affinity peptide which could specifically binds to interleukin-4 receptor (IL-4R), highly expressing on both glioma cells and angiogenesis. Our findings showed that the peptide-functionalized nanoparticles had a high affinity with both tumor cells and vascular endothelial cells. Besides, tumor targeting assay exhibited that AP1 decorated nanoparticles accumulated more in tumor site than the unmodified ones. Moreover, the results of tumor uptake experiments indicated that AP1-NP-DOX might own the ability of blood brain barrier (BBB) penetration. In the anti-glioma study, AP1-NP-DOX exhibited the highest therapeutic effect on tumor-bearing mice compared with the unmodified nanoparticles and free doxorubicin. These results together indicated that AP1-functionalized nanoparticles could represent a promising way to expand the treatment horizons of onco-therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|